On Monday, October 27, 2025, ORIC Pharmaceuticals presented a series of preclinical posters at the EORTC‑NCI‑AACR International Conference on Molecular Targets and Cancer Therapeutics in San Francisco and San Diego. The presentations highlighted ORIC‑944, the company’s allosteric PRC2 inhibitor targeting the EED subunit, and its potential as a best‑in‑class therapy for prostate cancer and other solid tumors.
Key findings from the posters showed that PRC2 inhibition enhances androgen‑receptor inhibitor response, delaying relapse in castration‑sensitive prostate cancer models by restricting tumor adaptation. In KRAS‑mutant lung and colorectal cancer models, PRC2 inhibition similarly potentiated KRAS inhibitor activity, extending the duration of response in preclinical studies.
ORIC‑944’s drug profile was reinforced by data demonstrating potent potency, favorable solubility, and a pharmacokinetic half‑life of approximately 20 hours, supporting once‑daily dosing. The compound also exhibited a robust safety profile and generated positive interim PSA response data in an ongoing Phase 1b trial (NCT05413421) combining ORIC‑944 with ERLEADA® (apalutamide) and NUBEQA® (darolutamide).
These results strengthen ORIC’s strategy to focus on ORIC‑944 and ORIC‑114, underscoring the company’s progress toward a best‑in‑class position and providing a solid foundation for its continued clinical development program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.